Pharmacovigilance – Webinars and Online Events
Ask Me Anything
Ask Me Anything: Body-on-a-Chip
Join Prof. Michael L. Shuler for a live session on "Body-on-a-Chip" technology. Discover its role in drug discovery, toxicity testing and disease modeling, plus insights into its future.
Webinar
Harnessing Molecular Drivers of Comorbidity for Precision Drug Discovery
In this webinar, Professor Jeffrey Skolnick will introduce POLYPHARM-AI, a suite of AI algorithms designed to identify common driver proteins shared across multiple comorbid diseases.
Webinar
Enhanced Analysis of Glycan Composition
On-Demand
This on-demand webinar explores how an electron-activated dissociation (EAD)-based LC-MS workflow provides a comprehensive approach to glycan analysis, enabling more accurate profiling and streamlined processes.
Webinar
Monitor Protein Therapeutic Color Changes With LC-MS
On-Demand
This webinar explores the implementation of a liquid chromatography mass spectrometry (LC-MS) workflow for peptide mapping to investigate and track these PTMs.
Webinar
Streamlined Identification of Targeted Protein Degrader Metabolites
On-Demand
This webinar highlights innovative solutions to these challenges, Ebru Selin Sele offers her insights into advanced methodologies for more efficient and accurate metabolite identification.
Webinar
Generation and Characterization of Retinal Organoids From iPSCs
On-Demand
In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.
Webinar
The Dash for NASH: How To Succeed in NASH Therapeutic Development
On-Demand
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.
Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.
Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?
Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.
Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?
Webinar
Protein Biomarker Models for Oncology Risk Assessment and Treatment Monitoring
On-Demand
In this webinar you will learn how the power of large-scale proteomics can be leveraged for multiple divergent applications in the field of oncology.
Webinar
Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes Session 2
On-Demand
Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity.
Webinar
Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes Session 1
On-Demand
Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity.
Advertisement
